StockData
Exagen Inc. logo

Exagen Inc. (XGN) stock

XGNNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30
$3.61−0.19 (-5.00%)

Close on Nov 20, 2026Market cap $87.45MP/E –Yield –

Exagen free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Exagen's free cash flow for the twelve months ending Jun 30, 2026 was -$7.59M. For fiscal 2025 it was -$14.27M. The highest annual figure on record is -$9.50M in fiscal 2018.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$14.27M–
FY2024Dec 31, 2024-$13.79M–
FY2023Dec 31, 2023-$15.29M–
FY2022Dec 31, 2022-$36.46M–
FY2021Dec 31, 2021-$22.64M–
FY2020Dec 31, 2020-$14.54M–
FY2019Dec 31, 2019-$10.11M–
FY2018Dec 31, 2018-$9.50M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$3.45M–
Q1 FY2026Mar 31, 2026-$10.65M–
Q4 FY2025Dec 31, 2025-$3.06M-1508.8%
Q3 FY2025Sep 30, 2025$2.67M–
Q2 FY2025Jun 30, 2025-$3.09M–
Q1 FY2025Mar 31, 2025-$10.78M–
Q4 FY2024Dec 31, 2024$217.00K-97.4%
Q3 FY2024Sep 30, 2024-$2.32M–
Q2 FY2024Jun 30, 2024-$2.56M–
Q1 FY2024Mar 31, 2024-$9.13M–
Q4 FY2023Dec 31, 2023$8.24M–
Q3 FY2023Sep 30, 2023-$2.91M–
Q2 FY2023Jun 30, 2023-$10.48M–
Q1 FY2023Mar 31, 2023-$10.15M–
Q4 FY2022Dec 31, 2022-$6.14M–
Q3 FY2022Sep 30, 2022-$7.56M–
Q2 FY2022Jun 30, 2022-$13.10M–
Q1 FY2022Mar 31, 2022-$9.66M–
Q4 FY2021Dec 31, 2021-$7.11M–
Q3 FY2021Sep 30, 2021-$5.89M–
Q2 FY2021Jun 30, 2021-$5.16M–
Q1 FY2021Mar 31, 2021-$4.48M–
Q4 FY2020Dec 31, 2020-$3.90M–
Q3 FY2020Sep 30, 2020-$2.34M–
Q2 FY2020Jun 30, 2020-$4.91M–
Q1 FY2020Mar 31, 2020-$3.39M–
Q4 FY2019Dec 31, 2019-$3.95M–
Q3 FY2019Sep 30, 2019-$1.67M–
Q2 FY2019Jun 30, 2019-$2.18M–
Q1 FY2019Mar 31, 2019-$2.31M–
Q4 FY2018Dec 31, 2018-$1.94M–

More Exagen figures

See a number that looks wrong?